Archives

Asthma, COPD Attacks Down With GLP-1 Drugs in the Picture

Thursday, September 10 – (MedPage Today) — Growing evidence linked GLP-1 drugs to a reduced risk of exacerbations of two types of chronic airways disease: asthma and chronic obstructive pulmonary disease (COPD).
Based on real-world records from the U.K., affected patients…

Menarini licenses Gan & Lee’s biweekly GLP-1 for Europe

Thursday, September 10 – Gan & Lee Pharmaceuticals Co. Ltd. has signed its largest ex-China licensing agreement for obesity candidate bofanglutide (GZR-18), granting Menarini Group rights across 39 European countries in a deal worth up to €726 million (US$844 million). Bofanglutide is a biweekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently discovered and developed by Beijing-based Gan & Lee.

Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop

Wednesday, September 9 – Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s amylin and calcitonin receptor agonist ACCG-2671 showed “impressive” target engagement in a Phase 1 trial of healthy volunteers, according to Leerink Partners.

Ozempic and Wegovy may have an unexpected mental health benefit

Wednesday, September 9 – Semaglutide, the drug behind Ozempic and Wegovy, may have benefits that extend well beyond weight loss and diabetes. In a large Swedish study of nearly 15,000 people with bipolar disorder, its use was linked to a 21% lower risk of psychiatric hospitalization. Researchers think effects on inflammation and brain-related biological pathways could help stabilize mood, though other GLP-1 drugs did not show the same association.

Semaglutide linked to 20% fewer COPD flare-ups and nearly 40% fewer asthma attacks

Wednesday, September 9 – The diabetes and weight-loss injection semaglutide can reduce asthma attacks by up to 40%, according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain. The study was led by Chloe Bloom, clinical associate professor in respiratory epidemiology at the National Heart & Lung Institute, Imperial College London, UK, and presented by Dr. Bohee Lee.

GLP-1 Drugs Like Zepbound Effectively Treat Sleep Apnea Alongside CPAP

Sunday, September 6 – A new review found that GLP-1s offer significant improvements in obstructive sleep apnea associated with obesity. vitapix/E+/Getty Images

New research has found that GLP-1 drugs may improve obstructive sleep apnea (OSA) related to obesity.

The effects of tirzepatide (Zepound), which is FDA approved for OSA, were especially notable.

GLP-1s appear to improve OSA associated with obesity by promoting fat loss in the neck, throat, and tongue.

CPAP therapy should be continued until a physician has confirmed remission with a sleep study.

GLP-1s May Be Taking Our Eyes Off the Real Obesity Problem

Sunday, September 6 – (MedPage Today) — GLP-1 receptor agonists may be powerful tools for treating obesity and cardiometabolic disease, but relying on medications alone risks overlooking the forces helping drive the obesity epidemic, according to Laura Schmidt, PhD…

Menarini licenses Gan & Lee’s biweekly GLP-1 for Europe

Sunday, September 6 – Gan & Lee Pharmaceuticals Co. Ltd. has signed its largest ex-China licensing agreement for obesity candidate bofanglutide (GZR-18), granting Menarini Group rights across 39 European countries in a deal worth up to €726 million (US$844 million). Bofanglutide is a biweekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently discovered and developed by Beijing-based Gan & Lee.